AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 616084148
Drug: 689 nm
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 689 nm laser treatment
Trial: 32653031
Drug: Monthly administration
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly administration of solid forms (tablets, capsules)
Trial: 32653031
Drug: Weekly administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly administration of solid forms (tablets, capsules)
Trial: 33040561
Drug: Remifentanil 1
RxNorm normalized name: remifentanil 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 1 μg/kg (Rem group, n=51)
Trial: 33040561
Drug: Propofol 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 1.0 mg/kg (Pro group, n=48)
Trial: 32736596
Drug: nebulised heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nebulised heparin
Trial: 35045185
Drug: Fosnetupitant (FosNTP)
RxNorm normalized name: fosnetupitant
DrugBank: Fosnetupitant (DB14019)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fosnetupitant (FosNTP) 235 mg
Trial: 35045185
Drug: Fosaprepitant (FosAPR)
DrugBank: Fosaprepitant (DB06717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fosaprepitant (FosAPR) 150 mg
Trial: 33930859
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment with 1 treatment-related SAE
Trial: 33930859
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment with 2 or more treatment-related SAEs
Trial: 35624452
Drug: Intravenous sildenafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sildenafil
Trial: 32828993
Drug: Wider implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wider implants (3.3 × 11.5 mm vs 4.2 × 11.5 mm)
Trial: 35640431
Drug: Fenfluramine (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenfluramine (0.2 mg/kg/day, titrated to a maximum of 0.7 mg/kg/day or 0.4 mg/kg/day with stiripentol)
Trial: 33838113
Drug: Voxelotor 1500
RxNorm normalized name: Voxelotor
DrugBank: Voxelotor (DB14975)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Voxelotor 1500 mg
Trial: 33838113
Drug: Voxelotor 900
RxNorm normalized name: Voxelotor
DrugBank: Voxelotor (DB14975)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Voxelotor 900 mg
Trial: 35258154
Drug: Cladribine tablets
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cladribine tablets 3.5 mg/kg (early cladribine)
Trial: 35258154
Drug: Cladribine tablets
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cladribine tablets 3.5 mg/kg (delayed cladribine)
Trial: 34137548
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination cream and oral tranexamic acid
Trial: 34137548
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination cream alone
Trial: 32334510
Drug: 0.5 μg·kg-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 μg·kg-1 DEX infusion (n=24)
Trial: 32334510
Drug: 1.0 μg·kg-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 μg·kg-1 DEX infusion (n=25)
Trial: 32334510
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (saline infusion, n=24)
Trial: 35961362
Drug: RotaTeq (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RotaTeq (3 doses at 6, 10, and 14 weeks)
Trial: 35961362
Drug: Rotarix (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotarix (2 doses at 6 and 10 weeks)
Trial: 35961362
Drug: RotaTeq (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RotaTeq (2 doses at 6 and 10 weeks)
Trial: 35961362
Drug: RotaTeq (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RotaTeq (3 doses)
Trial: 35961362
Drug: Rotarix (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotarix (2 doses)
Trial: 35775313
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy plus trastuzumab
Trial: 32233747
Drug: Alcohol and
RxNorm normalized name: Polyvinyl alcohol and povidone only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol and other drug users (AOD)
Trial: 35291694
Drug: IV alpha-1
RxNorm normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV alpha-1 antitrypsin (AAT) 120 mg/kg weekly
Trial: 34631601
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with emollients and topical corticosteroids plus dilute bleach baths (DBB)
Trial: 34631601
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with emollients and topical corticosteroids
Trial: 32318749
Drug: Intrathecal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal dexmedetomidine (5 μg, added to local anesthetics)
Trial: 32318749
Drug: Intravenous dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dexmedetomidine (1 μg/kg infused during 10 min before blockade)
Trial: 35266342
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of inappropriate medications
Trial: 35819327
Drug: Intravenous alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous alteplase added to EVT
Trial: 34252576
Drug: Transluminal injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transluminal injection of foam sclerotherapy (TLFS) with endovenous laser ablation (EVLA)
Trial: 32297754
Drug: Computerized cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerized cognitive-behavioral therapy (CBT4CBT)
Trial: 34260595
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with benazepril (10 mg/day) and valsartan (160 mg/day)
Trial: 34260595
Drug: Valsartan (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan (320 mg/day)
Trial: 34218992
Drug: Buprenorphine/naloxone (Bup/Nal)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine/naloxone (Bup/Nal) treatment for 12 weeks
Trial: 34218992
Drug: Weekly drug
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly drug counseling
Trial: 34174706
Drug: Unguided low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unguided low intensity cognitive behaviour therapy
Trial: 38729426
Drug: Subcutaneous administration
RxNorm normalized name: subcutaneous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration
Trial: 33130235
Drug: Verinurad (9mg)
RxNorm normalized name: Verinurad
DrugBank: Verinurad (DB11873)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verinurad (9mg) plus febuxostat (80mg) once daily for 24 weeks
Trial: 33130235
Drug: Matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo once daily for 24 weeks
Trial: 32893745
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E and ginseng supplement (100 IU vitamin E, 67 mg Korean ginseng, and 40 mg Siberian ginseng)
Trial: 36206298
Drug: Taxane-based chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taxane-based chemotherapy
Trial: 35437223
Drug: Oral magnesium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral magnesium chloride (MgCl2) for at least 4 months
Trial: 35437223
Drug: Oral magnesium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral magnesium chloride (MgCl2)
Trial: 32679405
Drug: Transoral surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transoral surgery followed by low- or standard-dose, risk-adjusted post-operative therapy
Trial: 33371454
Drug: High LF
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High LF (600 mg/day)
Trial: 33371454
Drug: Low LF
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low LF (200 mg/day)
Trial: 35900605
Drug: Test gel
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test gel containing propolis extract, nanovitamin C, and nanovitamin E applied 3 times/day for 4 weeks
Trial: 35900605
Drug: Control gel
RxNorm normalized name: SALICYLIC ACID 20 mg in 1 mL TOPICAL GEL [Walgreens Acne Control Gel]
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control gel applied 3 times/day for 4 weeks
Trial: 33782413
Drug: Oral oestroprogestogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral oestroprogestogen contraceptive (OC)
Trial: 33782413
Drug: Low-dose combination
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose combination of spironolactone-pioglitazone-metformin (SPIOMET)
Trial: 33782413
Drug: Post-OC treatment
RxNorm normalized name: OC 8 Adult Acne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-OC treatment
Trial: 33782413
Drug: Post-SPIOMET treatment
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-SPIOMET treatment
Trial: 32291813
Drug: 100 units
RxNorm normalized name: heparin 100 units/mL injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 units of intradermal BTX‐A
Trial: 32291813
Drug: Combined emollients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined emollients and topical mid‐potency steroid
Trial: 36261447
Drug: NGF injection
RxNorm normalized name: Panthenol 1 g in 100 mL TOPICAL SOLUTION [NGF 574H HAIR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NGF injection in masseter muscle
Trial: 36261447
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline injection in masseter muscle
Trial: 32106832
Drug: Bupropion 75
RxNorm normalized name: buPROPion 75 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion 75 mg/day for the first three days and 150 mg/day (divided in two doses) till the end of the study at week 6.
Trial: 32417634
Drug: Selenium yeast
RxNorm normalized name: Selenium Yeast
DrugBank: Selenium (DB11135)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium yeast (200 μg/day) and coenzyme Q10 (200 mg/day)
Trial: 39016010
Drug: Intensive SBP
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive SBP treatment
Trial: 34753667
Drug: Multi-component school-based
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-component school-based intervention (weekly supervised circuit exercise 30 min/week, health education session 10 min/week, lunchtime sports activities 20 min/week)
Trial: 32563378
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (1 g loading dose followed by 3 g maintenance dose over 24 hours)
Trial: 35147195
Drug: G-CSF (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (300 µg, 1.8 ml)
Trial: 35147195
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (1.8 ml)
Trial: 34294550
Drug: Cholecalciferol supplementation
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol supplementation (50,000 IU weekly for 12 weeks)
Trial: 34269257
Drug: Ketamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine infusion of 1 mg/kg/h
Trial: 34269257
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion of 1.5-6 mg/kg/h
Trial: 32101145
Drug: Preoperative forced-air
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative forced-air and intravenous fluid warming
Trial: 35883082
Drug: Menaquinone‐7 (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menaquinone‐7 (90 µg/day)
Trial: 36196478
Drug: FEP-medication group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FEP-medication group (second-generation antipsychotic medication)
Trial: 36196478
Drug: FEP-medication group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FEP-medication group
Trial: 34807661
Drug: Faster within-treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faster within-treatment improvement of PTSD symptoms
Trial: 36242831
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (24 IU), twice daily for three days
Trial: 32610330
Drug: Cold Therapy
RxNorm normalized name: Deep Cold Therapy
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold Therapy (CT)
Trial: 33397767
Drug: Bihormonal artificial
RxNorm normalized name: COLOR,ARTIFICIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bihormonal artificial pancreas (AP) therapy, 2-week duration
Trial: 33397767
Drug: Open loop
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open loop control (patient's normal insulin pump therapy), 2-week duration
Trial: 32044942
Drug: Incisional negative
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incisional negative pressure wound therapy (n=785)
Trial: 33522891
Drug: Ice slurry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ice slurry ingestion (1.25 g·kg body mass‐1 at -1°C) during HA training
Trial: 36198994
Drug: Fluconazole (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (150 mg) with 30 placebo capsules of probiotic
Trial: 36198994
Drug: Probiotic (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic (30 capsules containing 1 × 10^9 CFU/g LA‐5) with 1 fluconazole placebo capsule
Trial: 32701225
Drug: Ocriplasmin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ocriplasmin infusion during robot-assisted retinal vein cannulation
Trial: 32701225
Drug: Ocriplasmin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ocriplasmin infusion
Trial: 35247321
Drug: ZY-19489 1500
RxNorm normalized name: ZY-19489
DrugBank: ZY19489 (DB18062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZY-19489 1500 mg
Trial: 35247321
Drug: ZY-19489 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZY-19489 (300 mg) in fed state
Trial: 35247321
Drug: ZY-19489 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZY-19489 (300 mg) in fasted state
Trial: 35247321
Drug: ZY-19489 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZY-19489 (200 mg)
Trial: 35247321
Drug: ZY-19489 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZY-19489 (300 mg)
Trial: 35247321
Drug: ZY-19489 (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZY-19489 (900 mg)
Trial: 35247321
Drug: Pharmacokinetic-Pharmacodynamic model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacokinetic-Pharmacodynamic model simulation for 1100 mg
Trial: 35450456
Drug: 0.30% sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.30% sodium hyaluronate ocular gel
Trial: 35445520
Drug: SlowMo therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SlowMo therapy
Trial: 34648352
Drug: FOLFOX‐HAIC (oxaliplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX‐HAIC (oxaliplatin 130 mg/m2, leucovorin 400 mg/m2, fluorouracil bolus 400 mg/m2 on day 1, and fluorouracil infusion 2,400 mg/m2 for 24 hours, once every 3 weeks)
Trial: 34648352
Drug: TACE (epirubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TACE (epirubicin 50 mg, lobaplatin 50 mg, and lipiodol and polyvinyl alcohol particles)
Trial: 35237342
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin combined with vitamin E
Trial: 34701332
Drug: S1 maintenance
RxNorm normalized name: cenobamate
DrugBank: Cenobamate (DB06119)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: S1 maintenance therapy
Trial: 34856826
Drug: Acupuncture (standardized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture (standardized protocol, twice per week for 5 weeks)
Trial: 34678887
Drug: Epidural block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural block with 75 mg of bupivacaine plus 50 μg of fentanyl
Trial: 34678887
Drug: Spinal anesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anesthesia with 15 mg of bupivacaine and 50 μg fentanyl
Trial: 34678887
Drug: Saddle block
RxNorm normalized name: Saddle Block-22
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saddle block with 15 mg of bupivacaine and 50 μg of fentanyl
Trial: 34768161
Drug: K562/GM‐CSF vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K562/GM‐CSF vaccine
Trial: 32087684
Drug: Oral Sucrosomial®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Sucrosomial® iron
Trial: 32087684
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) iron gluconate
Trial: 33973256
Drug: Faces with
RxNorm normalized name: Face Up with Sulfur
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faces with distinctive features (e.g., tattoos)
Trial: 33245807
Drug: Cues to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cues to experience nature (e.g., smell flowers, observe wildlife, turn off your phone)
Trial: 33245807
Drug: Cues to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cues to experience nature (e.g., smell and touch natural elements)
Trial: 35135308
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K antagonist therapy
Trial: 35135308
Drug: Uninterrupted apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Uninterrupted apixaban and Vitamin K antagonist therapy
Trial: 34846698
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment only
Trial: 35713447
Drug: Institutional antiemetic
RxNorm normalized name: vilanterol
DrugBank: Vilanterol (DB09082)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Institutional antiemetic therapy alone
Trial: 35713447
Drug: Institutional antiemetic
RxNorm normalized name: vilanterol
DrugBank: Vilanterol (DB09082)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Institutional antiemetic therapy in combination with ginger (2 different concentrations)
Trial: 35790016
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy (control arm of five RCTs: ASCENT 2, VENICE, CELGENE/MAINSAIL, ENTHUSE 14, ENTHUSE 33)
Trial: 36054319
Drug: Clobetasol Propionate
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clobetasol Propionate ointment
Trial: 37753555
Drug: Traditional oral
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional oral hygiene instructions (OHI)
Trial: 34651102
Drug: Pamphlet of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamphlet of drug abuse prevention
Trial: 35501772
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) program
Trial: 36028775
Drug: Individual nutrition
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual nutrition therapy (five in-person visits and three phone calls) and freely delivered energy- and protein-rich foods
Trial: 33636344
Drug: Behavioral intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Behavioral intervention including nudges within the electronic health record (EHR) such as accountable justification, precommitment to address high-risk prescriptions, and PainTracker.
Trial: 33212438
Drug: IG3: combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IG3: combination of IG1 and IG2
Trial: 32798761
Drug: Layer‐by‐layer wound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Layer‐by‐layer wound irrigation with gentamicin‐saline solution
Trial: 32798761
Drug: Wound irrigation
RxNorm normalized name: Prontosan Wound Irrigation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wound irrigation with saline solution